MS drug safety knowledge put to the test in european survey
NCT ID NCT05301907
First seen Jan 06, 2026 · Last updated May 22, 2026 · Updated 27 times
Summary
This completed study surveyed 335 healthcare professionals and people with multiple sclerosis (or their caregivers) in Europe. The goal was to see if they understood the safety steps needed when using the drug Mayzent (siponimod). Participants answered questions about proper use, side effects, and risks. The study did not test a new treatment but rather checked how well educational materials work.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Basel, Switzerland
Conditions
Explore the condition pages connected to this study.